Who has been named CFO of BioNexus Gene Lab Corp, and what regulatory filing was submitted regarding their ownership?

Chong Set Fui has been named CFO of BioNexus Gene Lab Corp, and the company filed an initial Form 3 for him with the U.S. SEC on June 17, 2025. This filing is a required disclosure under Section 16(a) of the Securities Exchange Act of 1934, reporting the initial beneficial ownership of the company's common stock by its officers and directors. The news brief clarifies that it was generated by AI from the EDGAR filing and serves informational purposes only—not financial advice—and that BioNexus Gene Lab Corp. is solely responsible for the original content submitted to the SEC.

What is the significance of the Form 3 filing dated June 17, 2025, for Chong Set Fui in relation to BioNexus Gene Lab Corp?

The Form 3 filing dated June 17, 2025, represents Chong Set Fui’s initial report of beneficial ownership of BioNexus Gene Lab Corp’s common stock, as mandated by SEC rules for corporate insiders such as officers and directors. It marks the formal commencement of his public disclosure obligations under Section 16(a), indicating he has assumed a position requiring transparency about personal holdings in the company’s securities. The filing was submitted via the SEC’s EDGAR system, and the AI-generated news brief explicitly states it is derived solely from that filing and carries no advisory intent—reiterating that BioNexus Gene Lab Corp. bears full responsibility for the accuracy and completeness of the original submission to the SEC.

BioNexus Gene Lab Names CFO Chong Set Fui in Initial Beneficial Ownership Filing

Aug 1, 2026

BioNexus Gene Lab Corp filed an initial Form 3 for CFO Chong Set Fui on June 17, 2025, disclosing beneficial ownership details to the U.S. Securities and Exchange Commission.

Bitget

BioNexus Gene Lab Names CFO Chong Set Fui in Initial Beneficial Ownership Filing

Bitget

BioNexus Gene Lab Names CFO Chong Set Fui in Initial Beneficial Ownership Filing

Bitget

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings